Holen Sie sich die Stockscreener-App
1.01
0.98%
-0.01
Handel nachbörslich:
.99
-0.02
-1.98%
Schlusskurs vom Vortag:
$1.02
Offen:
$1.02
24-Stunden-Volumen:
52,363
Relative Volume:
0.19
Marktkapitalisierung:
$32.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-11.45
EPS:
-0.0882
Netto-Cashflow:
-
1W Leistung:
-10.62%
1M Leistung:
+30.31%
6M Leistung:
-90.56%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.00
$1.05
1-Wochen-Bereich:
$0.9527
$1.19
52-Wochen-Spanne:
$0.51
$19.51
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Firmenname
Jupiter Neurosciences Inc
Sektor
Branche
Telefon
(561) 406-6154
Adresse
1001 NORTH US HWY 1, JUPITER
Vergleichen Sie JUNS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
1.01 | 32.01M | 0 | 0 | 0 | -0.0882 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten
Jupiter Neurosciences’ Innovative Strategy in Biotech: A Dual Approach to Success - citybuzz -
How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success - FinancialContent
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Jupiter Neurosciences launches Nugevia longevity products By Investing.com - Investing.com South Africa
Jupiter Neurosciences launches resveratrol-powered supplements - Longevity.Technology
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Jupiter Neurosciences launches Nugevia longevity products - Investing.com
Jupiter Neurosciences Launches Nugevia™: A Premium - GlobeNewswire
Jupiter Neurosciences Targets $8T Longevity Market with Revolutionary 9x More Effective Supplement Line - Stock Titan
IsoEnergy Announces Launch of At-The-Market Equity Program - The Globe and Mail
Certain Restricted Stock Units of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Certain Common Stock of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Certain Options of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
Jupiter Neurosciences appoints new auditor amid transition By Investing.com - Investing.com Nigeria
Jupiter Neurosciences appoints new auditor amid transition - Investing.com Australia
Jupiter Neurosciences targets Parkinson’s and longevity markets By Investing.com - Investing.com South Africa
Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development - marketscreener.com
Jupiter Neurosciences targets Parkinson's and longevity markets - Investing.com
Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant - Stock Titan
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com India
Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire
Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks
Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa
Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com
Jupiter Neurosciences partners with Aquanova on health products - Investing.com
Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
Finanzdaten der Jupiter Neurosciences Inc-Aktie (JUNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):